G

GemPharmatech Co Ltd
SSE:688046

Watchlist Manager
GemPharmatech Co Ltd
SSE:688046
Watchlist
Price: 13.53 CNY -1.24% Market Closed
Market Cap: 5.5B CNY
Have any thoughts about
GemPharmatech Co Ltd?
Write Note
GemPharmatech Co Ltd
/
Balance Sheet
/
PP&E Net

GemPharmatech Co Ltd
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

GemPharmatech Co Ltd
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
G
GemPharmatech Co Ltd
SSE:688046
PP&E Net
¥628.7m
CAGR 3-Years
56%
CAGR 5-Years
191%
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
PP&E Net
¥26.8B
CAGR 3-Years
22%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
PP&E Net
¥10.4B
CAGR 3-Years
27%
CAGR 5-Years
31%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
PP&E Net
¥30.8B
CAGR 3-Years
20%
CAGR 5-Years
50%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
PP&E Net
¥1.5B
CAGR 3-Years
14%
CAGR 5-Years
34%
CAGR 10-Years
28%
W
WuXi XDC Cayman Inc
HKEX:2268
PP&E Net
¥1.2B
CAGR 3-Years
60%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

GemPharmatech Co Ltd
Glance View

Market Cap
5.5B CNY
Industry
Life Sciences Tools & Services

GemPharmatech Co., Ltd. engages in research and development, manufacture, and sale of experimental mouse models. The company is headquartered in Nanjing, Jiangsu and currently employs 1,342 full-time employees. The company went IPO on 2022-04-25. The firm uses gene-editing and other technologies to produce mouse models. The firm also involves in the business of customized model breeding, drug efficacy analysis, and model customization. The Company’s products are mainly used to satisfy the experimental demands in the fields of gene function cognition, disease mechanisms analysis, drug target discovery, and other fundamental researches.

Intrinsic Value
21.04 CNY
Undervaluation 36%
Intrinsic Value
Price
G
What is Intrinsic Value?

See Also

What is GemPharmatech Co Ltd's PP&E Net?
PP&E Net
628.7m CNY

Based on the financial report for Dec 31, 2023, GemPharmatech Co Ltd's PP&E Net amounts to 628.7m CNY.

What is GemPharmatech Co Ltd's PP&E Net growth rate?
PP&E Net CAGR 5Y
191%

Over the last year, the PP&E Net growth was 59%. The average annual PP&E Net growth rates for GemPharmatech Co Ltd have been 56% over the past three years , 191% over the past five years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.